Hospital
Mainehealth
Mainehealth was paid $40.06M by Medicaid between Jan 2018 and Dec 2024, across 459 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 30% of everything it billed.
33Billing provider infoMAINEHEALTH
BRUNSWICK, ME 04011
BRUNSWICK, ME 04011
33aNPI1932164795assigned 04/17/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$40.06M
24GClaims1,121,670
24DCodes billed459
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Maine
Rank by total paid#4 of 33
Median peer was paid$4.34M
This provider vs. median9.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official INZANA, LUGENE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 142,797 | $3.99M | |
| 2019 | 150,374 | $4.63M | |
| 2020 | 134,505 | $4.37M | |
| 2021 | 151,126 | $5.51M | |
| 2022 | 179,022 | $6.89M | |
| 2023 | 185,428 | $6.96M | |
| 2024incomplete | 178,418 | $7.71M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 30% | 166,332 | 129,378 | $12.19M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 13% | 8,901 | 7,989 | $5.02M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 11% | 21,346 | 18,397 | $4.42M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 4.2% | 12,428 | 11,432 | $1.68M |
| 90853 | Group psychotherapy (other than of a multiple-family group) | 2.6% | 14,603 | 3,859 | $1.06M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.5% | 10,080 | 8,798 | $1.02M |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 1.7% | 1,241 | 858 | $667K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.3% | 3,392 | 3,256 | $527K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.3% | 5,861 | 5,469 | $508K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.2% | 22,582 | 8,396 | $500K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 1.1% | 12,395 | 11,976 | $441K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.0% | 7,473 | 7,044 | $419K |
447 more codes
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 11,854 | $362K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,956 | $349K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 4,096 | $338K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,853 | $318K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 1,027 | $303K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 8,273 | $294K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 16,459 | $275K |
| 64450 | <1% | 1,191 | $272K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 11,701 | $256K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,561 | $251K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 7,423 | $249K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 16,907 | $229K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 7,594 | $209K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 3,297 | $209K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 396 | $206K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 387 | $205K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,130 | $201K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 10,807 | $201K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 1,892 | $184K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 1,954 | $168K |
| 20610 | <1% | 1,398 | $161K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,349 | $155K |
| 59025 | Fetal non-stress test | <1% | 1,258 | $146K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 2,338 | $144K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 2,191 | $139K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 3,304 | $134K |
| 76830 | Ultrasound, transvaginal | <1% | 1,594 | $124K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 14,122 | $122K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 1,816 | $116K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,536 | $115K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 6,143 | $113K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 538 | $112K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,071 | $110K |
| G0008 | Administration of influenza virus vaccine | <1% | 3,739 | $107K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 121 | $104K |
| 76801 | <1% | 1,206 | $103K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 1,184 | $100K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 295 | $98K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 175 | $91K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 1,338 | $90K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 778 | $86K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 1,258 | $85K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 4,916 | $82K |
| 80053 | Comprehensive metabolic panel | <1% | 41,058 | $82K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 12,060 | $81K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 1,168 | $78K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 4,282 | $77K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,276 | $76K |
| 86900 | <1% | 2,425 | $76K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 6,262 | $72K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 672 | $71K |
| 80061 | Lipid panel | <1% | 9,000 | $70K |
| 97161 | <1% | 1,785 | $69K | |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 1,157 | $68K |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 35 | $67K |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 866 | $65K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 44,619 | $62K |
| 97162 | <1% | 2,233 | $62K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 4,245 | $61K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 4,240 | $61K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 13 | $61K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 512 | $60K |
| G0009 | Administration of pneumococcal vaccine | <1% | 1,780 | $57K |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 968 | $55K |
| 71250 | <1% | 1,416 | $55K | |
| 64405 | <1% | 799 | $54K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 893 | $54K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 3,579 | $54K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,649 | $51K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 109 | $49K |
| 90677 | <1% | 995 | $49K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 2,650 | $48K |
| 92587 | <1% | 225 | $46K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,754 | $42K |
| 36415 | Collection of venous blood by venipuncture | <1% | 64,917 | $41K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 1,560 | $41K |
| 73564 | <1% | 1,965 | $40K | |
| 64615 | <1% | 402 | $40K | |
| 0001A | <1% | 1,386 | $37K | |
| 0002A | <1% | 1,293 | $37K | |
| 87481 | <1% | 4,005 | $36K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 11,076 | $36K |
| 94060 | <1% | 387 | $36K | |
| 93971 | <1% | 732 | $35K | |
| 90686 | <1% | 5,446 | $35K | |
| 94726 | <1% | 997 | $35K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 2,258 | $35K |
| 99307 | <1% | 3,654 | $34K | |
| 87510 | <1% | 2,272 | $33K | |
| 87480 | <1% | 2,272 | $33K | |
| 87660 | <1% | 2,272 | $33K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 368 | $31K |
| 82728 | <1% | 4,209 | $29K | |
| 92588 | <1% | 129 | $27K | |
| 72141 | <1% | 209 | $27K | |
| G0410 | Group psychotherapy other than of a multiple-family group, in a partial hospitalization or intensive outpatient setting, approximately 45 to 50 minutes | <1% | 2,301 | $24K |
| 72100 | <1% | 959 | $24K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 6,947 | $24K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 276 | $24K |
| 90670 | <1% | 2,553 | $24K | |
| 82607 | <1% | 3,745 | $24K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 985 | $24K |
| 93017 | <1% | 638 | $24K | |
| 73630 | <1% | 1,490 | $23K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 705 | $23K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 1,288 | $22K |
| 90473 | <1% | 551 | $20K | |
| 86780 | <1% | 1,770 | $20K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 9,148 | $19K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,901 | $19K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 9,324 | $19K |
| 74018 | <1% | 904 | $19K | |
| 73030 | <1% | 1,487 | $19K | |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 237 | $18K |
| 87511 | <1% | 2,039 | $18K | |
| 88142 | <1% | 1,325 | $18K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 2,052 | $17K |
| 84702 | <1% | 2,413 | $17K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,850 | $17K |
| 73610 | <1% | 1,244 | $16K | |
| 73110 | <1% | 940 | $16K | |
| 90480 | <1% | 832 | $15K | |
| G0400 | Home sleep test (hst) with type iv portable monitor, unattended; minimum of 3 channels | <1% | 82 | $15K |
| 76642 | <1% | 292 | $15K | |
| 73130 | <1% | 1,089 | $14K | |
| 31575 | <1% | 149 | $14K | |
| 91320 | <1% | 349 | $14K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 210 | $14K |
| 99188 | <1% | 552 | $14K | |
| 86803 | <1% | 3,577 | $13K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 57 | $13K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 16,298 | $13K |
| J7298 | Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg | <1% | 14 | $13K |
| 99223 | Prolong inpt eval add15 m | <1% | 207 | $13K |
| 90651 | <1% | 1,418 | $12K | |
| 70496 | <1% | 130 | $12K | |
| 76536 | <1% | 228 | $12K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 475 | $11K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 68 | $10K |
| 84439 | <1% | 2,089 | $10K | |
| 87070 | <1% | 3,124 | $10K | |
| 59430 | <1% | 56 | $10K | |
| 73140 | <1% | 591 | $9K | |
| 92557 | <1% | 485 | $8K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 268 | $8K |
| 86140 | <1% | 6,397 | $8K | |
| 97035 | <1% | 1,347 | $8K | |
| 83540 | <1% | 2,720 | $8K | |
| 85027 | <1% | 4,150 | $8K | |
| 97116 | <1% | 1,082 | $7K | |
| 0124A | <1% | 512 | $7K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 191 | $7K |
| 99001 | <1% | 3,360 | $7K | |
| 83970 | <1% | 715 | $7K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 12 | $7K |
| 84466 | <1% | 1,013 | $7K | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 303 | $7K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 480 | $6K |
| 86618 | <1% | 1,394 | $6K | |
| 87186 | <1% | 2,984 | $6K | |
| 73502 | <1% | 550 | $6K | |
| 99406 | <1% | 408 | $6K | |
| 92551 | <1% | 586 | $6K | |
| 90837 | Psychotherapy session, about an hour | <1% | 68 | $6K |
| 91322 | <1% | 152 | $6K | |
| 85610 | <1% | 5,278 | $6K | |
| 99495 | <1% | 136 | $5K | |
| 87340 | <1% | 2,167 | $5K | |
| 90734 | <1% | 701 | $5K | |
| 83550 | <1% | 1,606 | $5K | |
| 0054A | <1% | 275 | $5K | |
| 76775 | <1% | 141 | $5K | |
| Q3014 | Telehealth originating site facility fee | <1% | 347 | $5K |
| 99490 | Ccm add 20min | <1% | 352 | $5K |
| 83735 | <1% | 10,590 | $5K | |
| G0378 | Hospital observation service, per hour | <1% | 6,285 | $5K |
| 88342 | <1% | 593 | $4K | |
| 96127 | <1% | 623 | $4K | |
| 97165 | <1% | 132 | $4K | |
| 95911 | <1% | 14 | $4K | |
| 94010 | <1% | 410 | $4K | |
| 87077 | <1% | 3,158 | $4K | |
| 93976 | <1% | 55 | $4K | |
| 87493 | <1% | 289 | $4K | |
| 82950 | <1% | 917 | $4K | |
| 85652 | <1% | 4,171 | $4K | |
| 90678 | <1% | 13 | $4K | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 121 | $4K |
| 83516 | <1% | 638 | $4K | |
| 83655 | <1% | 781 | $3K | |
| 96415 | <1% | 118 | $3K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 3,896 | $3K |
| 87522 | Neg quan hep c or qual rna | <1% | 236 | $3K |
| 82784 | <1% | 766 | $3K | |
| 90656 | <1% | 558 | $3K | |
| 87081 | <1% | 1,692 | $3K | |
| 97597 | <1% | 48 | $3K | |
| 70486 | <1% | 52 | $3K | |
| 81001 | <1% | 10,667 | $3K | |
| 82043 | <1% | 1,591 | $3K | |
| 80076 | <1% | 715 | $3K | |
| 99308 | Subsequent nursing facility care, per day, straightforward | <1% | 169 | $3K |
| 81025 | <1% | 5,863 | $3K | |
| 90461 | <1% | 196 | $3K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 354 | $3K |
| 99496 | <1% | 41 | $3K | |
| 97802 | <1% | 40 | $2K | |
| 82746 | <1% | 423 | $2K | |
| 84588 | <1% | 730 | $2K | |
| 76000 | <1% | 165 | $2K | |
| 83690 | <1% | 7,548 | $2K | |
| 73562 | <1% | 179 | $2K | |
| 84403 | <1% | 146 | $2K | |
| 86706 | <1% | 428 | $2K | |
| 95800 | <1% | 26 | $2K | |
| 58300 | <1% | 57 | $2K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 271 | $2K |
| 73600 | <1% | 217 | $2K | |
| 87468 | <1% | 434 | $2K | |
| 80050 | General health panel | <1% | 94 | $2K |
| 87469 | <1% | 433 | $2K | |
| 83880 | <1% | 894 | $2K | |
| 72050 | <1% | 40 | $2K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 85 | $2K |
| 73221 | <1% | 12 | $2K | |
| 97803 | <1% | 73 | $2K | |
| 69210 | <1% | 252 | $2K | |
| 82570 | <1% | 1,071 | $1K | |
| 86762 | <1% | 1,093 | $1K | |
| 77080 | <1% | 36 | $1K | |
| 92550 | <1% | 97 | $1K | |
| 90662 | <1% | 276 | $1K | |
| 81003 | <1% | 7,133 | $1K | |
| 80178 | <1% | 485 | $1K | |
| 97163 | <1% | 55 | $1K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 48 | $1K |
| 84156 | <1% | 1,213 | $1K | |
| 86850 | <1% | 2,417 | $1K | |
| 84100 | <1% | 912 | $1K | |
| 99174 | <1% | 84 | $1K | |
| 90732 | <1% | 26 | $1K | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 14 | $1K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,394 | $1K |
| 90674 | <1% | 213 | $1K | |
| 77066 | Tomosynthesis, mammo | <1% | 14 | $1K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 44 | $1K |
| 85018 | <1% | 1,149 | $1K | |
| 86704 | <1% | 170 | $962.77 | |
| 76770 | <1% | 13 | $906.01 | |
| 99442 | <1% | 48 | $883.11 | |
| 76820 | <1% | 118 | $871.67 | |
| 86364 | <1% | 271 | $859.97 | |
| 84550 | <1% | 723 | $804.54 | |
| 85014 | <1% | 585 | $794.07 | |
| 85379 | <1% | 1,673 | $793.57 | |
| 83993 | <1% | 57 | $776.19 | |
| 84153 | <1% | 67 | $771.20 | |
| 93225 | <1% | 13 | $750.08 | |
| 82550 | <1% | 476 | $693.39 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,168 | $662.87 |
| 86481 | <1% | 14 | $660.50 | |
| 51798 | <1% | 732 | $656.77 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 56 | $612.83 |
| 72170 | <1% | 15 | $581.19 | |
| G0010 | Administration of hepatitis b vaccine | <1% | 16 | $567.72 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 5,957 | $544.56 |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | <1% | 53 | $540.49 |
| 82948 | <1% | 5,223 | $523.51 | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 13 | $523.09 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 8,056 | $506.89 |
| 80074 | <1% | 13 | $505.67 | |
| 94729 | <1% | 947 | $483.66 | |
| 82565 | <1% | 329 | $445.01 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,035 | $440.98 |
| 88304 | <1% | 401 | $435.99 | |
| 99000 | <1% | 121 | $428.03 | |
| 87653 | <1% | 1,227 | $425.92 | |
| 86480 | <1% | 12 | $409.31 | |
| 73501 | <1% | 13 | $386.41 | |
| 76882 | <1% | 28 | $379.37 | |
| 70498 | <1% | 135 | $377.91 | |
| 96381 | <1% | 27 | $358.56 | |
| 81002 | <1% | 4,816 | $357.48 | |
| 99443 | <1% | 14 | $355.34 | |
| 82105 | <1% | 71 | $353.49 | |
| J2704 | Injection, propofol, 10 mg | <1% | 7,311 | $346.04 |
| 99309 | Subsequent nursing facility care, per day, low to moderate complexity | <1% | 13 | $317.48 |
| 86038 | <1% | 80 | $298.30 | |
| 87040 | <1% | 1,127 | $286.97 | |
| 0082A | <1% | 24 | $283.50 | |
| 84484 | <1% | 8,218 | $282.38 | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 12 | $280.78 |
| 84450 | <1% | 211 | $273.50 | |
| 99173 | <1% | 423 | $266.49 | |
| 87205 | <1% | 513 | $266.29 | |
| 84703 | <1% | 1,987 | $246.33 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 523 | $242.73 |
| 92504 | <1% | 155 | $239.93 | |
| 80069 | <1% | 94 | $237.72 | |
| 83718 | <1% | 48 | $230.86 | |
| 90681 | <1% | 1,372 | $217.44 | |
| 90744 | <1% | 861 | $215.35 | |
| 73100 | <1% | 34 | $214.92 | |
| 82040 | <1% | 279 | $193.95 | |
| 90716 | <1% | 563 | $187.68 | |
| 87634 | <1% | 69 | $181.98 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 831 | $176.29 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 610 | $165.58 |
| 84402 | <1% | 13 | $152.82 | |
| 90620 | <1% | 14 | $147.37 | |
| D1206 | Topical application of fluoride varnish | <1% | 12 | $144.00 |
| 87046 | <1% | 12 | $141.60 | |
| 84146 | <1% | 14 | $135.66 | |
| 90619 | <1% | 400 | $134.22 | |
| 87484 | <1% | 12 | $122.80 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 4,246 | $121.84 |
| 82465 | <1% | 49 | $120.60 | |
| 86003 | <1% | 12 | $120.06 | |
| 90649 | <1% | 98 | $120.00 | |
| 83605 | <1% | 1,468 | $119.63 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 9,619 | $108.89 |
| 80164 | <1% | 29 | $108.32 | |
| 84460 | <1% | 78 | $106.65 | |
| 92567 | <1% | 864 | $106.05 | |
| G0411 | Interactive group psychotherapy, in a partial hospitalization or intensive outpatient setting, approximately 45 to 50 minutes | <1% | 2,802 | $102.24 |
| 0154A | <1% | 29 | $101.70 | |
| 85730 | <1% | 143 | $98.77 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 6,290 | $90.90 |
| 86039 | <1% | 13 | $89.28 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,766 | $78.05 |
| 83721 | <1% | 12 | $74.96 | |
| 86334 | <1% | 15 | $71.49 | |
| 83615 | <1% | 66 | $70.82 | |
| 73560 | <1% | 14 | $70.01 | |
| 87430 | <1% | 276 | $69.26 | |
| 86308 | <1% | 14 | $68.77 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,766 | $65.48 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,809 | $65.29 |
| 87420 | <1% | 322 | $58.55 | |
| 87427 | <1% | 12 | $58.55 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,321 | $55.76 |
| 92015 | Determination of refractive state | <1% | 396 | $55.30 |
| J3490 | Unclassified drugs | <1% | 611 | $47.80 |
| 87045 | <1% | 12 | $47.20 | |
| 86708 | <1% | 12 | $46.52 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,308 | $39.78 |
| 86431 | <1% | 12 | $38.07 | |
| 84165 | <1% | 15 | $34.37 | |
| 82947 | <1% | 12 | $32.08 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 389 | $30.62 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,061 | $30.20 |
| 83037 | <1% | 247 | $29.13 | |
| 90715 | <1% | 3,179 | $28.69 | |
| 12001 | <1% | 27 | $27.54 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,290 | $23.26 |
| 92134 | <1% | 59 | $15.90 | |
| 82805 | <1% | 43 | $15.75 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,848 | $15.07 |
| 85008 | <1% | 208 | $14.67 | |
| 87807 | <1% | 100 | $11.71 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,380 | $10.41 |
| 96376 | <1% | 2,445 | $7.29 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 657 | $6.90 |
| 84132 | <1% | 15 | $4.69 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 62 | $4.29 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 596 | $2.70 |
| 90723 | <1% | 806 | $2.00 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 851 | $0.41 |
| 91305 | 0% | 277 | $0.00 | |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 241 | $0.00 |
| 90698 | 0% | 1,071 | $0.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 1,004 | $0.00 |
| 90474 | 0% | 724 | $0.00 | |
| 86901 | 0% | 2,425 | $0.00 | |
| C1819 | Surgical tissue localization and excision device (implantable) | 0% | 67 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 942 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 328 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 920 | $0.00 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 0% | 234 | $0.00 |
| 36416 | 0% | 1,117 | $0.00 | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 548 | $0.00 |
| 90696 | 0% | 228 | $0.00 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 1,125 | $0.00 |
| 90697 | 0% | 516 | $0.00 | |
| V2632 | Posterior chamber intraocular lens | 0% | 237 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 91 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 35 | $0.00 |
| C1769 | Guide wire | 0% | 117 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 420 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 174 | $0.00 |
| C9399 | Unclassified drugs or biologicals | 0% | 62 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 53 | $0.00 |
| J2280 | Injection, moxifloxacin, 100 mg | 0% | 85 | $0.00 |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | 0% | 475 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 77 | $0.00 |
| 0081A | 0% | 17 | $0.00 | |
| G2058 | Chronic care management services, each additional 20 minutes of clinical staff time directed by a physician or other qualified health care professional, per calendar month (list separately in addition to code for primary procedure). (do not report g2058 for care management services of less than 20 minutes additional to the first 20 minutes of chronic care management services during a calendar month). (use g2058 in conjunction with 99490). (do not report 99490, g2058 in the same calendar month as 99487, 99489, 99491)). | 0% | 17 | $0.00 |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 16 | $0.00 |
| 95886 | 0% | 37 | $0.00 | |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 59 | $0.00 |
| 91307 | 0% | 29 | $0.00 | |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 52 | $0.00 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 17 | $0.00 |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 0% | 17 | $0.00 |
| C1773 | Retrieval device, insertable (used to retrieve fractured medical devices) | 0% | 14 | $0.00 |
| 82803 | 0% | 24 | $0.00 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 918 | $0.00 |
| 90633 | 0% | 2,003 | $0.00 | |
| 76937 | 0% | 419 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 257 | $0.00 |
| 90710 | 0% | 592 | $0.00 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 271 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 1,358 | $0.00 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 629 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 383 | $0.00 |
| 90700 | 0% | 673 | $0.00 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | 0% | 6,877 | $0.00 |
| 76376 | 0% | 290 | $0.00 | |
| G0177 | Training and educational services related to the care and treatment of patient's disabling mental health problems per session (45 minutes or more) | 0% | 8,734 | $0.00 |
| G0176 | Activity therapy, such as music, dance, art or play therapies not for recreation, related to the care and treatment of patient's disabling mental health problems, per session (45 minutes or more) | 0% | 2,707 | $0.00 |
| 90707 | 0% | 564 | $0.00 | |
| 91300 | 0% | 2,013 | $0.00 | |
| 90648 | 0% | 527 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 199 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 308 | $0.00 |
| 76942 | 0% | 86 | $0.00 | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | 0% | 216 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 153 | $0.00 |
| 91312 | 0% | 360 | $0.00 | |
| 91308 | 0% | 121 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 53 | $0.00 |
| 99204 | Doctor's office visit, new patient (more involved) | 0% | 26 | $0.00 |
| 90671 | 0% | 302 | $0.00 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 240 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 163 | $0.00 |
| 91321 | 0% | 217 | $0.00 | |
| 93356 | 0% | 260 | $0.00 | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 258 | $0.00 |
| 77003 | 0% | 79 | $0.00 | |
| 90713 | 0% | 34 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 33 | $0.00 |
| H0015 | Alcohol and/or drug services; intensive outpatient (treatment program that operates at least 3 hours/day and at least 3 days/week and is based on an individualized treatment plan), including assessment, counseling; crisis intervention, and activity therapies or education | 0% | 102 | $0.00 |
| 0004A | 0% | 43 | $0.00 | |
| J1756 | Injection, iron sucrose, 1 mg | 0% | 113 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 50 | $0.00 |
| 92133 | 0% | 14 | $0.00 | |
| 93325 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialINZANA, LUGENE (MH ASSOCIATE CFO)
| Provider | Location | Paid |
|---|---|---|
| Mainehealth | Portland, ME | $142.72M |
| Mainehealth | Portland, ME | $115.05M |
| Mainehealth | Biddeford, ME | $70.83M |
| Mainehealth | Farmington, ME | $22.62M |
| Mainehealth | Biddeford, ME | $10.89M |
| Mainehealth | Falmouth, ME | $6.54M |
| Mainehealth | Portland, ME | $5.46M |
| Mainehealth | Scarborough, ME | $5.04M |
| Mainehealth | Rockport, ME | $4.34M |
| Mainehealth | Scarborough, ME | $4.16M |
| Mainehealth | Portland, ME | $4.09M |
| Mainehealth | Scarborough, ME | $3.94M |
| Mainehealth | Portland, ME | $3.55M |
| Mainehealth | Waldoboro, ME | $3.43M |
| Mainehealth | Scarborough, ME | $3.18M |
| Mainehealth | Brunswick, ME | $2.77M |
| Mainehealth | Portland, ME | $2.68M |
| Mainehealth | Falmouth, ME | $2.10M |
| Mainehealth | Portland, ME | $1.87M |
| Mainehealth | Cape Elizabeth, ME | $1.82M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.